Please try another search
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company’s lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Name | Age | Since | Title |
---|---|---|---|
Roger A. Fielding | - | 2016 | Member of Scientific Advisory Board |
Jose-Alain Sahel | - | - | Member of Scientific Advisory Board |
Nadine Coulm | 61 | 2015 | Independent Director |
Jean Mariani | 74 | 2016 | Chairman of Scientific Advisory Board & Director |
Thomas Voit | - | 2017 | Member of Scientific Advisory Board |
Stanislas Veillet | 59 | 2015 | Chairman of the Board & CEO |
Rene Lafont | 78 | 2011 | Scientific Advisor & Member of Scientific Advisory Board |
Yann Meunier | - | 2023 | Member of Scientific Advisory Board |
Claude Allary | 69 | 2021 | Independent Director |
Dennis Villareal | - | 2024 | Member of Scientific Advisory Board |
Bernard Levy | - | 2023 | Member of Scientific Advisory Board |
Francisco Guarner | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review